Clinuvel Pharmaceuticals Limited
ASX:CUV.AX
14.98 (AUD) • At close September 18, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Clinuvel Pharmaceuticals Limited |
Symbool | CUV.AX |
Munteenheid | AUD |
Prijs | 14.98 |
Beurswaarde | 750,165,444 |
Dividendpercentage | 0.33% |
52-weken bereik | 12.96 - 18.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA |
Website | https://www.clinuvel.com |
An error occurred while fetching data.
Over Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)